Genetic Risk Factors Associated With Antiemetic Efficacy of Palonosetron, Aprepitant, and Dexamethasone in Japanese Breast Cancer Patients Treated With Anthracycline-based Chemotherapy
| Autor: | Shoichiro Ohtani, Takaaki Ao, Keiki Kawakami, Tomokazu Yamakawa, Satoshi Tamaru, Kenichi Watanabe, Takuya Iwamoto, Kazuya Ooi, Shinichi Kageyama, Tomomi Yamada, Makoto Simomura, Yasuhiko Sakata, Toshiro Mizuno, Susumu Ban, Akiya Mori, Satoshi Yokoyama, Naomi Konishi, Daisuke Nakanishi, Shinya Tamaki |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty Antiemetic Agent Anthracycline medicine.drug_class Nausea Vomiting Breast Neoplasms 030226 pharmacology & pharmacy Polymorphism Single Nucleotide Dexamethasone 03 medical and health sciences 0302 clinical medicine Breast cancer Risk Factors Internal medicine medicine Odds Ratio Antiemetic ATP Binding Cassette Transporter Subfamily G Member 2 Humans Anthracyclines Genetic Predisposition to Disease Prospective Studies Aprepitant Antibiotics Antineoplastic business.industry Palonosetron Middle Aged medicine.disease Neoplasm Proteins Treatment Outcome 030220 oncology & carcinogenesis Antiemetics Female medicine.symptom business Chemotherapy-induced nausea and vomiting medicine.drug |
| Zdroj: | Clinical breast cancer. 18(2) |
| ISSN: | 1938-0666 |
| Popis: | Introduction Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been associated with poor clinical outcomes and shorter survival. The aim of the present study was to identify genetic risk factors associated with anthracycline-based CINV. Patients and Methods We evaluated CINV attributable to anthracycline-based chemotherapy in Japanese breast cancer patients treated with an antiemetic regimen that included palonosetron, aprepitant, and dexamethasone. Furthermore, we investigated the associations between CINV and single nucleotide polymorphisms in 6 candidate genes. Results Emesis episodes were rarely observed in the 125 patients included in the present survey (7.2%; n = 9); however, significant nausea occurred in more than one half of the patients (52.8%; n = 66). In particular, acute significant nausea was not effectively controlled. Multivariate logistic regression analysis revealed that the ABCG2 (rs2231142) AA genotype is significantly associated with acute significant nausea (odds ratio, 4.87; 95% confidence interval, 1.01-23.60; P = .049). Conclusion The findings of the present study provide significant insights for developing personalized antiemetic strategies for breast cancer patients receiving anthracycline-based chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect